Release Date: March 18, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: With regard to attrition rates, are there any attrition numbers due to technical issues? A: Matthew Foehr, President and CEO, stated that the attrition observed was not related to technical issues. Instead, it was primarily due to big pharma pipeline realignment, which is a normal part of the drug development process. The company experienced a strong quarter in terms of additions, positioning them well for the year.
Q: Can you provide more information on the new technology rollouts planned for this year? A: Kurt Gustafson, CFO, mentioned that OmniAb is committed to innovation, which is a significant competitive advantage. The company plans to launch new technologies that will enable the discovery of high-quality candidates more efficiently. These innovations are expected to expand existing partnerships and attract new ones. The launches are aligned with key scientific conferences, such as the PEGs Protein Engineering Conference in May and the AET Conference in December.
Q: In the current volatile markets, do you anticipate additional pipeline and development leading to increased cash deployment from partners? A: Matthew Foehr noted that OmniAb's business has been resilient across various cycles. The scalable and flexible nature of their platforms positions them well in different market landscapes, allowing them to adapt to various industry cycles and research approaches.
Q: Regarding the 2025 revenue guidance of $20 to $25 million, what portion is expected to be cash versus non-cash? A: Kurt Gustafson explained that the guidance is a GAAP number. The decrease in revenue compared to 2024 is primarily due to a reduction in non-cash service revenue. The deferred service revenue balance is now down to $2.5 million, indicating a decrease in non-cash revenue for 2025.
Q: Are you seeing any impact on academic partnerships due to market volatility and NIH funding concerns? A: Matthew Foehr stated that, so far, there has been no impact on their academic partnerships. OmniAb continues to engage in active dialogue with prospective academic partners, and they recently signed a new deal with a leading academic institution interested in leveraging their technology.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.